Pharmacology & Toxicology Department >
Dr. Godugu Chandraiah >
Dr. Manoj Dandekar >
Dr. Nitin Pal Kalia >
Dr. Santosh Kumar Guru >
Dr. Dharmendra Khatri>

Faculty Profile : Dr. Nitin Pal Kalia

Name: Dr. Nitin Pal Kalia

Assistant Professor
+91 40 23074750 Extn- 2048
Google Scholar Citations
ORCID ID: 0000-0003-4346-6567
SCOPUS ID: 25221481600
Web of Science Researcher ID:


Department of Pharmaccology and Toxicology
Room No: 63
NIPER Hyderabad
Department of Pharmaceuticals (Govt. of India)
Balanagar, Hyderabad - 500037, TS, INDIA


  1. Assistant Professor, Department of Biological Sciences at NIPER Hyderabad - February 2021 - Present
  2. Ramalingaswami Fellow: CSIR-IIIM Jammu (Aug-2019 to Jan 2021)
  3. Research Fellow: Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (Oct 2015 to Aug 2019).
  4. Visiting Fellow: Tuberculosis Research Section, NIAID/LCID/ National Institutes of Health Bethesda Maryland USA (May 2014 to July 2015).


  1. Ph.D (2014): CSIR-IIIM Jammu/BVU Pune, India.
  2. M.Sc (2006): Guru Nanak Dev University, Amritsar Punjab, India.
  3. B.Sc (2004): Himachal Pradesh University Shimla, India.


M.S. (Pharm.) - Pharmacology & Toxicology: PC 660 and PC 650


PhD : Ongoing: 01


  1. IIIM-CSIR Jammu, award for significant contribution in Discovery Biology-For identification of novel scaffolds for tuberculosis (September 2013).
  2. Sponsored by Department of Biotechnology Govt. of India for industrial training under Biotech Industrial Training Program (February 2007- July 2007).


Microbiology/ Infectious Diseases/ Drug Discovery

My group 's major research involves identification and characterization of new chemical entities for their anti-infective properties. Drug Discovery against Mycobacterium tuberculosis (Mtb), Non Tuberculous mycobacteria, Gram Negative bacteria and ESKAPE pathogens is prime focus of research. The drug discovery program involves development of in-vitro screening assays and supporting assays to decipher mechanism of action of molecules using molecular biology approaches and biochemical assays followed by in-vivo evaluation of identified molecules using mice model for infection.

  • Targeting Persistence in Mtb : Long-term chemotherapy for tuberculosis is responsible for emergence to multi-drug resistant Mtb strains and persistence is the major cause for long-term tuberculosis chemotherapy therefore targeting persistence will be helpful in reducing the treatment duration as well as emergence of MDR-Mtb.
  • Targeting resistance in Nosocomial Pathogens : Drug resistance is very common among nosocomial pathogens hence Gram-negative bacteria and ESKAPE pathogens, which are responsible for hospital-acquired infections, will serve as another area of research for drug discovery. Apart from identifying direct hits, we will also focus on molecules (resistant breakers) which enhances the efficacy of existing antibiotics against resistant bacteria.


1. Funding Agency: Department of Biotechnology
Project Title: Targeting the cytochrome bd oxidase for development of rational drug combination for tuberculosis.
Amount Sanctioned: 113.60 Lakhs (Salary + Contingency (1st and 2nd year: 10 Lakh/per year; 3rd and 4th year: 7.5 lakh/per year and 5th year: 5 lakh))
Sanctioned Date: 19-Nov-2018 (Sanction Number: D.O.NO. BT/HRD/35/02/2006)
Project Started from: 09-Aug-2019
Closing Date: 08-Aug-2024


  1. Awarded Ramalingaswami Re-entry Fellowship (2017-2018) by Department of Biotechnology (DBT) Govt. of India.
  2. Awarded Indian Council of Medical Research-Senior Research Fellowship on the research project entitled Evaluation of capsaicin and its structural analogues as multidrug efflux pump inhibitors of Staphylococcus aureus" (letter no. 80/665/2010- ECD-1, dated31-12-2010).


  1. Hopfner, S.M.; Lee, B.S.; Kalia, N.P.; Miller, M.J.; Pethe, K.; Moraski, G.C. (2021) Syntheses and Structure Activity Relationships of N-Phenethyl-Quinazolin-4-yl-Amines as Potent Inhibitors of Cytochrome bd Oxidase in Mycobacterium tuberculosis. Appl. Sci. 2021, 11, 9092. doi: 10.3390/app11199092.
  2. Thomas S.S.,; Kalia N.P.,; Pethe K. (2022) Turbidity-Based MIC Assay and Characterization of Spontaneous Drug Resistant Mutants in Mycobacterium ulcerans. Methods Mol Biol. 2387:209-217. doi: 10.1007/978-1-0716-1779-3_20
  3. Hopfner SM, Lee BS, Nitin P. Kalia, Miller MJ, Pethe K, Moraski GC. Structure guided generation of thieno[3,2-d] pyrimidin-4-amine Mycobacterium tuberculosis bd oxidase inhibitors. RSC Medicinal Chemistry, : DOI: 10.1039/ d0md00398k.
  4. Lee BS, Hards K, Engelhart CA, Hasenoehrl EJ, Nitin P. Kalia, Mackenzie JS, Sviriaeva E, Chong SMS, Manimekalai MSS, Koh VH, Chan J, Xu J, Alonso S, Miller MJ, Steyn AJC, Grber G, Schnappinger D, Berney M, Cook GM, Moraski GC, Pethe Kevin (2020) Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis. EMBO Medicine, 13(1):e13207.
  5. Thomas SS, Nitin P. Kalia, Ruf MT, Pluschke G, Pethe K. (2020) Toward a Single-Dose Cure for Buruli Ulcer. Antimicrobial Agents and Chemotherapy. doi:10.1128/aac.00727-20.
  6. Hotra A, Ragunathan P, Ng PS, Seankongsuk P, Harikishore A, Sarathy JP, Saw WG, Lakshmanan U, Lao PS, Nitin P. Kalia, Shin J, Kalyanasundaram R, Anbarasu S, Krupakar P, Pradeep CN, Makhija H, Drge P, Poulsen A, Tan JHL, Pethe K, Dick T, Bates RW, Grber G. (2020) Discovery of a novel Mycobacterial F-ATP synthase inhibitor and its potency in combination with diarylquinolines. Angewandte Chemie International Edition. doi: 10.1002/anie.202002546.
  7. Nitin P. Kalia, Lee BS, Rahman NB, Moraski GC, Miller MJ, Pethe K (2019) Carbon metabolism modulates the efficacy of drugs targeting the cytochrome bc1:aa3 in Mycobacterium tuberculosis. Scientific Reports, 9(1):8608, doi: 10.1038/s41598-019-44887-9.
  8. Scherr N, Bieri1 R, Thomas SS, Chauffour A, Nitin P. Kalia, Schneide P, Ruf M, Lamelas A, Manimekalai MSS, Grber G, Ishii N, Suzuki K, Tanner M, Moraski GC, Miller MJ, Witschel M, Jarlier V, Pluschke G, Pethe K. (2018) Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer. Nature Communications, 18; 9(1):5370. doi: 10.1038/s41467-018-07804-8.
  9. Bei SL, Nitin P. Kalia, Jin X Er F, Hasenoehrl EJ, Berney M, Pethe K. (2018) Inhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria. Journal of Biological Chemistry, 294(6);1936-1943,jbc.RA118.005732. doi:10.1074/jbc.RA118.005732.
  10. Nitin P. Kalia, Hasenoehrl EJ, Rahman NB, Koh VH, Ang MLT., Sajordab DR., Hardse K., Grber G., Alonso S., Cooke GM., Berney M., PetheK. (2017) Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection. Proceedings of National Academy of Sciences USA,114(28):7426-7431, doi: 10.1073/pnas.1706139114.
  11. Nitin P. Kalia, Mahajan P, Mehra R, Nargotra A, Sharma JP, Koul S, Khan IA. (2012) Capsaicin, a novel inhibitor of NorA efflux pump reduces the intracellular invasion of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 67: 24012408.


Nitin P. Kalia (2017): Efflux-Mediated Drug Resistance in Staphylococcus aureus. Drug Resistance in Bacteria, Fungi, Malaria, and Cancer Springer, Cham pp 307-323


  1. Subramanyam R, Thumm LD, Qazi GN, Khan IA, Suri KA, Satti NK, Ali F, Nitin Pal Kalia. Chalcones as enhancer of Antimicrobial Agents. (Status Granted, WO 2011/075136 A1, PCT/US2009/068688:Filed to US patent agency,).
  2. Kamal A, Shetti VCRNC, Swapna P, Shaik A, Reddy AM, Khan IA, Abdullah ST, Sharma S, Nitin Pal Kalia. Synthesis of new and novel benzothiazole conjugates as potential anti-tubercular agents.(Patent No.: US 9,949,970 B2, Date: Apr. 24, 2018, United States Patent).
  3. Singh PP, Munagala G, Kushalava RY, Khan IA, Nitin Pal Kalia, Rajput VS, Nargotra A, Sawant SD, Vishwakarma RA. 6-nitro-2, 3-dihydroimidazo [2, 1-b] oxazoles and a process for the preparation thereof. (Patent No.: US 9, 845,330 B2, Date: Dec. 19, 2017, United States Patent).
  4. Kamal A, Viswanath A, Murty JNSC, Sulthana F, Ramakrishna G, Khan IA, Nitin Pal Kalia. Nitrofurfuryl-substituted phenyl-linked piperidino-oxadiazolin conjugates as tuberculosis agents and methods for their preparation. (Patent No.: US 9,108,960 B2, Date: Aug. 18, 2015, United States Patent).




  1. Establishing Biosafety level-2 labs for handling of pathogenic bacteria.